Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Christina Annette Bjerre"'
Autor:
Andreas Hagen Røssevold, Nikolai Kragøe Andresen, Christina Annette Bjerre, Bjørnar Gilje, Erik Hugger Jakobsen, Sunil Xavier Raj, Ragnhild Sørum Falk, Hege Giercksky Russnes, Thea Jahr, Randi Ruud Mathiesen, Jon Lømo, Øystein Garred, Sudhir Kumar Chauhan, Ragnhild Reehorst Lereim, Claire Dunn, Bjørn Naume, Jon Amund Kyte
Publikováno v:
Nature Medicine
Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast cancer (mTNBC) but only for PD-L1positive disease. The randomized, placebo-controlled ALICE trial (NCT03164993) evaluated the addition of atezolizumab (anti-PD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5be76fcfa7bb190d32d4cf113604ee9b
https://hdl.handle.net/11250/3059007
https://hdl.handle.net/11250/3059007
Autor:
Jon Amund Kyte, Andreas H. Røssevold, Nikolai K. Andresen, Christina Annette Bjerre, Bjørnar Gilje, Erik Hugger Jakobsen, Sunil Xavier Raj, Ragnhild Sørum Falk, Elin Borgen, Thea Jahr, Øystein Garred, Jon Lømo, Randi Margit Mathiesen, Bjørn Naume
Publikováno v:
Cancer Research. 83:PD11-11
Background: Immune checkpoint inhibitors (CPI) have shown efficacy against metastatic triple negative breast cancer (mTNBC), but only for PD-L1 positive tumors. It is not known if so-called immunogenic chemotherapies may yield clinical relevant syner
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd41b039af94b1b54eaf3d7c105f41f4
https://doi.org/10.1158/1538-7445.sabcs22-pd11-11
https://doi.org/10.1158/1538-7445.sabcs22-pd11-11
Autor:
Christina Annette Bjerre, Anne Vibeke Lænkholm, Ann Knoop, Henrik J. Ditzel, Birgitte Bruun Rasmussen, Bent Ejlertsen, Katrine L Henriksen, Maria Bibi Lyng, Karsten Bjerre, Mathilde S. Larsen, Nils Brünner
Publikováno v:
Bjerre, C A, Knoop, A, Bjerre, K, Larsen, M S, Henriksen, K L, Lyng, M B, Ditzel, H J, Rasmussen, B B, Brünner, N, Ejlertsen, B L & Lænkholm, A-V 2013, ' Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer ', Acta Oncologica, vol. 52, no. 1, pp. 82-90 . https://doi.org/10.3109/0284186X.2012.734922
Background. The role of tissue inhibitor of metalloproteinases-1 (TIMP-1) in estrogen receptor (ER) positive breast cancer remains to be fully elucidated. We evaluated TIMP-1 as a prognostic marker in patients treated with adjuvant tamoxifen and inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dbb2c2b274a0ff5f51aab8f848a3d7d
https://doi.org/10.3109/0284186x.2012.734922
https://doi.org/10.3109/0284186x.2012.734922
Autor:
Charlotte Jørgensen, Annette Bartels, Nils Brünner, Christina Annette Bjerre, Dorte Lisbet Nielsen, Karsten Bjerre, Eva Balslev, Bent Ejlertsen
Publikováno v:
BMC Cancer
Jørgensen, C L T, Bjerre, C A, Ejlertsen, B L, Bjerre, K D, Balslev, E, Bartels, A, Brünner, N & Nielsen, D L 2014, ' TIMP-1 and responsiveness to gemcitabine in advanced breast cancer : results from a randomized phase III trial from the Danish breast cancer cooperative group ', B M C Cancer, vol. 14, 360 . https://doi.org/10.1186/1471-2407-14-360
Jørgensen, C L T, Bjerre, C A, Ejlertsen, B L, Bjerre, K D, Balslev, E, Bartels, A, Brünner, N & Nielsen, D L 2014, ' TIMP-1 and responsiveness to gemcitabine in advanced breast cancer : results from a randomized phase III trial from the Danish breast cancer cooperative group ', B M C Cancer, vol. 14, 360 . https://doi.org/10.1186/1471-2407-14-360
Background: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has anti-apoptotic functions, which may protect TIMP-1 positive cancer cells from the effects of chemotherapy such as docetaxel and gemcitabine. The purpose of the present study was to eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbe352e115bfaa287aa57e38097a1122
https://doi.org/10.1186/1471-2407-14-360
https://doi.org/10.1186/1471-2407-14-360
Autor:
Ramneek Gupta, L Bolund, B.S. Nielsen, Christina Annette Bjerre, Jun Wang, Vibeke Jensen, Ulrik Lademann, Lena Vinther, R Soekilde, Nils Brünner, Jan Stenvang, X Lin, Jian Li, Rasmussen A-S Schrohl, Z Han, K Belling
Publikováno v:
Cancer Research. 71:P4-01
Background Endocrine resistance represents a major challenge in the management of estrogen receptor (ER) positive breast cancer. Currently no predictive biomarkers for endocrine resistance in ERpositive breast cancer patients are in clinical use. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4248b1cea523a88e78ccd808352c17b6
https://doi.org/10.1158/0008-5472.sabcs11-p4-01-17
https://doi.org/10.1158/0008-5472.sabcs11-p4-01-17
Autor:
Henrik J. Ditzel, Nils Brünner, Ann Knoop, A-V Lænkholm, Maria Bibi Lyng, A. Bartels, Christina Annette Bjerre
Publikováno v:
Bjerre, C, Knoop, A, Lyng, M B, Ditzel, H, Brünner, N, Bartels, A & Lænkholm, A V 2009, ' TIMP-1 status measured by immunohistochemistry in 268 ER positive postmenopausal high-risk breast cancer patients treated with adjuvant Tamoxifen: association to recurrence free survival ', 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, United States, 09/12/2009-13/12/2009 .
Background: A proportion of ER positive breast cancer patients do not benefit from adjuvant tamoxifen treatment. Tamoxifen has been shown to induce apoptosis in human breast cancer cells in vitro and Tissue Inhibitor of Metalloproteinases-1 (TIMP-1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ec2233cc18d21fcf7dd9e61f6c9059f
https://doi.org/10.1158/0008-5472.sabcs-09-2025
https://doi.org/10.1158/0008-5472.sabcs-09-2025